You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Monday, April 18<br />
Poster Session 8:30 a.m.–7:00 p.m.<br />
8:30 a.m.–7:00 p.m. Poster Session<br />
P3 Poster Session III<br />
Presenters Stand by Posters 5:30 p.m.–7:00 p.m.<br />
Poster Discussion Session: MS and CNS Inflammatory Disease<br />
Eight abstracts have been selected for presentation during a poster discussion session. Authors will present a 5-minute<br />
data blitz presentation.<br />
In addition to the regular poster time, authors also have a specific time slot over lunch. Times below are standard<br />
across poster sessions.<br />
Discussion: 11:45 a.m.–11:50 a.m.<br />
P3.001 Myelin Oligodendrocyte<br />
Glycoprotein Antibodies Are Associated<br />
with Bilateral and Recurrent Optic Neuritis<br />
and Have a Distinct Radiological Profile<br />
to Multiple Sclerosis or Aquaporin-4<br />
Antibody-associated Optic Neuritis —<br />
Sudarshini Ramanathan, Kristina Prelog,<br />
Elizabeth Barnes, Esther Tantsis, Stephen<br />
Reddel, Andrew Henderson, Ostoja Vucic,<br />
Mark Gorman, Leslie Benson, Gulay Alper,<br />
Catherine Riney, Michael Barnett, John<br />
Parratt, Todd Hardy, Richard Leventer, Vera<br />
Merheb, Margherita Nosadini, Victor Fung,<br />
Fabienne Brilot, Russell Dale<br />
Discussion: 11:50 a.m.–11:55 a.m.<br />
P3.002 Lifetime Sun Exposure and<br />
the Risk of Multiple Sclerosis in Blacks<br />
and Hispanics —Annette Langer-Gould, Lie<br />
Chen, Edlin Gonzales, Christopher Schroeder,<br />
Anny Xiang, Lisa Barcellos, Robyn Lucas<br />
Discussion: 11:55 a.m.–12:00 p.m.<br />
P3.003 Epidemiology of Aquaporin-4<br />
Autoimmunity and Neuromyelitis<br />
Optica Spectrum: A Comparison of Two<br />
Ethnically Divergent Populations —Eoin<br />
Flanagan, Philippe Cabre, Brian Weinshenker,<br />
JenniferSt. Sauver, Masoud Majed, Vanda<br />
Lennon, Claudia Lucchinetti, Andrew McKeon,<br />
Dean Wingerchuk, Jayawant Mandrekar,<br />
Debra Jacobson, Jessica Sagen, John<br />
Schmeling, James Fryer, Marcelo Matiello,<br />
Nilifur Kale, Angala Borders Robinson, Sean<br />
Pittock<br />
Discussion: 12:00 p.m.–12:05 p.m.<br />
P3.004 Novel Findings in Anti-GABAa<br />
Receptor Encephalitis —Marianna Spatola,<br />
Mar Petit-Pedrol, Myrna Rosenfeld, Francesc<br />
Graus, Josep Dalmau<br />
Discussion: 12:05 p.m.–12:10 p.m.<br />
P3.005 Multiple Sclerosis White<br />
Matter Demyelination and Remyelination<br />
Using T1-, T2- and T2*-Weighted Images:<br />
A Post Mortem Validation Study at<br />
7.0 Tesla —Michael Bradshaw, Assunta<br />
Dal-Bianco, Simon Hametner, Siddharama<br />
Pawate, Subramaniam Sriram, Seth Smith,<br />
John Gore, Brian Welch, Hans Lassmann,<br />
Francesca Bagnato<br />
Discussion: 12:10 p.m.–12:15 p.m.<br />
P3.006 Vitamin D Supplementation<br />
Reduces Markers of Oxidative Stress<br />
Measured by Untargeted Metabolomics<br />
in Healthy Controls but Not in Multiple<br />
Sclerosis Patients —Pavan Bhargava,<br />
Kathryn Fitzgerald, Sonya Steele, Sandra<br />
Cassard, Emmanuelle Waubant, Peter<br />
Calabresi, Ellen Mowry<br />
Discussion: 12:15 p.m.–12:20 p.m.<br />
P3.007 The Role of Gut Immunity in<br />
Multiple Sclerosis Patients —Vittorio<br />
Martinelli, Maria Josè Messina, Mariani<br />
Alberto, Ilaria Cosorich, Gloria Dalla Costa,<br />
Gloria Dalla Costa, Mariaemma Rodegher,<br />
Giancarlo Comi, Marika Falcone<br />
Discussion: 12:20 p.m.–12:25 p.m.<br />
P3.008 Progressive Solitary Sclerosis:<br />
Insidious Motor Impairment Localized<br />
to an Isolated CNS Demyelinating<br />
Lesion —Mark Keegan, Timothy Kaufmann,<br />
Brian Weinshenker, Orhun Kantarci, William<br />
Schmalstieg, M. Paz Soldan, Eoin Flanagan<br />
e-Poster Session: MS and CNS Inflammatory Disease<br />
Ten e-posters in six neurologic topics have been selected for on-site, interactive display. e-Posters will be grouped in a separate<br />
area where attendees are invited to explore more deeply through touch screen displays.<br />
P3.009 Contrasting In Situ and In Vitro<br />
Expression of MiR-155 and MiR-146a<br />
in Astrocytes in Context of Multiple<br />
Sclerosis (MS)—Vijayaraghava Rao, Samuel<br />
Ludwin, Shih-Chieh Fuh, Marthe Minderman,<br />
Robin Sawaya, Craig Moore, Ming-Kai Ho,<br />
Barry Bedell, Jack Antel<br />
P3.010 Dimethyl Fumarate Is Well<br />
Tolerated in a Small Cohort of Pediatric-<br />
Onset Multiple Sclerosis Patients —Ian<br />
Rossman, Manikum Moodley, Mary Rensel<br />
P3.011 Movement Measurements<br />
At Home for Multiple Sclerosis: Walking<br />
Speed and Cane Usage Measured by a<br />
Novel Infrared Sensor —Victoria M. Smith,<br />
Jonathan Varsanik, Kevin Patel, Wendy<br />
Gabel, Glenn Phillips, Zebadiah Kimmel, Eric<br />
Klawiter<br />
P3.012 Racial Variations in Mean<br />
Serum Vitamin A (Retinoic Acid) Levels in<br />
Multiple Sclerosis Patients with Normal/<br />
Corrected Vitamin D Levels —Bijal Mehta,<br />
Kristen Berube<br />
P3.013 Automatic Measurement of<br />
Optic Nerve Atrophy in Multiple Sclerosis<br />
Patients with and Without Optic Neuritis<br />
in MRI —Robert Harrigan, Bennett Landman,<br />
Louise Mawn, Siddharama Pawate, Seth Smith<br />
P3.014 MS Arising During Tocilizumab<br />
Therapy for Rheumatoid Arthritis —<br />
Philippe Beauchemin, Robert Carruthers<br />
P3.015 Time Course of Multiple<br />
Sclerosis Lesions Visualized with MRI:<br />
Insight into Focal Pathology —Pietro<br />
Maggi, Francesco Zellini, Alessandro Barilaro,<br />
Alessandro Passeri, Luca Massacesi<br />
P3.016 MRI Quantification of Spinal<br />
Cord Atrophy in Multiple Sclerosis: A<br />
Systematic Review and Meta-Analysis —<br />
Courtney Casserly, Stephanie Sankar, Stefan<br />
Baral, Jiwon Oh<br />
P3.017 Autoimmune Tumefactive<br />
Rhombencephalitis Associated with Anti-<br />
TNFα (Adalimumab) Treatment —Kedar<br />
Mahajan, Omar Shah<br />
P3.018 Assessment of High-<br />
Resolution, Clinically Applicable<br />
Quantitative Magnetization Transfer<br />
Imaging in the Cervical Spinal Cord of<br />
Multiple Sclerosis Patients at 3T —Alex<br />
Smith, Richard Dortch, Bailey Lyttle,<br />
Siddharama Pawate, Seth Smith<br />
MS and CNS Inflammatory Disease:<br />
Clinical Trials<br />
P3.019 Absence of HDL Decrease<br />
After Interferon Beta-1a Initiation Is<br />
Associated with Greater Brain Volume<br />
Loss and Lesion Burden in Multiple<br />
Sclerosis Patiens over 4 Years —Tomas<br />
Uher, Dana Horakova, Kelly Fellows, Manuela<br />
Vaneckova, Lukas Sobisek, Zdenek Seidl,<br />
Michaela Tyblova, Jan Krasensky, Eva<br />
Havrdova, Murali Ramanathan<br />
P3.020 Relationship Between VLA-4<br />
Receptor Occupancy and Body Weight<br />
in Natalizumab Treated Patients —John<br />
Foley, Tamara Hoyt, Angelene Christensen,<br />
Ryan Metzger<br />
P3.021 Early Vs Delayed Treatment<br />
with Teriflunomide 14 Mg Results in<br />
Reduced Risk of Disability Progression<br />
in Patients with MS —Paul O'Connor,<br />
Karthinathan Thangavelu, Pascal Rufi,<br />
Philippe Truffinet<br />
P3.022 Patients with Active RRMS and<br />
an Inadequate Response to Prior Therapy<br />
Demonstrate Durable Improvements<br />
in Relapse and Disability Following<br />
Treatment with Alemtuzumab: 5-Year<br />
Follow-Up of the CARE-MS II Study —<br />
Alasdair Coles, Douglas Arnold, Jeffrey<br />
Cohen, Edward Fox, Gavin Giovannoni,<br />
Hans-Peter Hartung, Eva Havrdova, Krzysztof<br />
Selmaj, David Margolin, Karthinathan<br />
Thangavelu, D. Alastair Compston<br />
P3.023 Results from the 48-Week<br />
Blinded Extension of RADIANCE: A<br />
Randomized, Double-Blind, Placebo-<br />
Controlled Phase 2 Trial of Oral Ozanimod<br />
in Relapsing Multiple Sclerosis —Krzysztof<br />
Selmaj, Jeffrey Cohen, Douglas Arnold,<br />
Giancarlo Comi, Amit Bar-Or, Sheila Gujrathi,<br />
Jeffrey Hartung, Allan Olson, Matthew<br />
Cravets, Paul Frohna<br />
68 2016 AAN Annual Meeting Abstract Listing
Change language